MindLight™
The first antidepressant response test using brain-derived biomarkers
MindLight is the first-ever circular RNA-based response test designed to predict if a patient with Major Depressive Disorder (MDD) will respond to selective serotonin reuptake inhibitor (SSRI) antidepressant treatment. Current standard of care involves a lengthy trial-and-error approach when evaluating a patient's responsiveness to medications for MDD. Circular Genomics is aiming to improve the standard of care by streamlining the treatment selection process with the MindLight Antidepressant Response Test.
Our company
Circular Genomics is dedicated to improving the treatment journey for patients affected by mental health disorders through the use of circular RNA biomarkers. Our team of globally recognized experts is striving to create a better understanding of mental health and brain conditions by leveraging precision medicine.
